[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410437":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":33,"responsibleParty":52,"collaborators":31,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":31,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":31,"enrollmentInfo":65,"targetDuration":31,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":80,"overallStatus":35,"whyStopped":31,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hyperpolarized 129Xe","EXPERIMENTAL","Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.",[13],"Drug: Hyperpolarized Xe129",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Hyperpolarized Xe129","During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.",[9],[21],"HP Xenon",[23],{"name":24,"affiliation":5,"role":25},"Peter Niedbalski, PHD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Cristal Monge","CONTACT","913-945-9399",null,"chernandez@kumc.edu",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Kansas City","Kansas","66160","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-94.62746,39.11417,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":31,"email":51},"Peter J Niedbalski, PhD","9135882271","pniedbalski@kumc.edu",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Mario Castro, MD, MPH","Division Chief, Pulmonary, Critical Care and Sleep Medicine","100410437","phase-1-hyperpolarized-129xe-mr-imaging-of-lung-function-in-healthy-volunteers-and-subjects-with-pulmonary-disease-100410437",false,"NCT04624490","Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease","Inclusion Criteria:\n\nHealthy Volunteers:\n\n* Subject has no diagnosed pulmonary conditions\n* Ability to read and understand English or Spanish\n\nSubjects with Lung Disease:\n\n* Subject has a diagnosis of pulmonary dysfunction made by a physician\n* No acute worsening of pulmonary function in the past 30 days\n* Ability to read and understand English or Spanish\n\nExclusion Criteria:\n\n* MRI is contraindicated based on responses to MRI screening questionnaire\n* Subject is pregnant or lactating\n* Subject does not fit into 129Xe vest coil used for MRI\n* Subject cannot hold his\u002Fher breath for 15-16 seconds\n* Subject deemed unlikely to be able to comply with instructions during imaging\n* Oxygen saturation \\\u003C88% on room air or with supplemental oxygen\n* Cognitive deficits that preclude ability to provide consent\n* Institutionalization",true,"ALL","3 Years",{"count":66,"type":67},260,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.",[73,74,75,76,77,78,79],"Asthma","COPD","Interstitial Lung Disease","Cystic Fibrosis","Pulmonary Hypertension","Pulmonary Infection","Other Lung Disease",[81],"Hyperpolarized 129Xe MRI","2026-04-30",{"date":84,"type":85},"2026-05-06","ACTUAL",{"date":87,"type":85},"2020-11-02",{"date":89,"type":67},"2028-10-26",{"name":54,"class":6},1]